Request Deal Involvement

Cormorant Asset Management led a $150m Series B funding round in Rapport Therapeutics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Latham & Watkins

legal advisors

Latham & Watkins

Ten Bridge Communications

pr advisors

Ten Bridge Communications

or

Principals

SOFINNOVA INVESTMENTS

bidder

SOFINNOVA INVESTMENTS

T. ROWE PRICE GROUP INC

bidder

T. ROWE PRICE GROUP INC

SURVEYOR CAPITAL

bidder

SURVEYOR CAPITAL

FIDELITY MANAGEMENT & RESEARCH COMPANY

bidder

FIDELITY MANAGEMENT & RESEARCH COMPANY

GOLDMAN SACHS ASSET MANAGEMENT

bidder

GOLDMAN SACHS ASSET MANAGEMENT

LOGOS CAPITAL

bidder

LOGOS CAPITAL

RAPPORT THERAPEUTICS INC

target

RAPPORT THERAPEUTICS INC

PERCEPTIVE ADVISORS LLC

bidder

PERCEPTIVE ADVISORS LLC

JOHNSON & JOHNSON INNOVATION - JJDC INC

bidder

JOHNSON & JOHNSON INNOVATION - JJDC INC

CORMORANT ASSET MANAGEMENT

bidder

CORMORANT ASSET MANAGEMENT

THIRD ROCK VENTURES LLC

bidder

THIRD ROCK VENTURES LLC

ARCH VENTURE PARTNERS

bidder

ARCH VENTURE PARTNERS

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Cormorant Asset Management led a $150m Series B funding round in Rapport Therapeutics.